Prognostic Value of the Systemic Immune-Inflammation Index in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

< .0001) across various study designs, regions, and sample sizes. Elevated SII was significantly linked to MACE in STEMI patients, though not in NSTEMI patients. Additionally, high SII levels correlated AMI is divided into high SII group and low SII group. There is a significant correlation between the incidence of no-reflow in the high SII group with increased risks of no-reflow post-percutaneous coronary intervention (PCI), left ventricular adverse remodeling, and all-cause mortality, regardless of study factors (ie, research type, population characteristics, region, and sample size). Elevated SII is a significant predictor of adverse outcomes in AMI patients, especially for forecasting MACE in STEMI cases.